Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Other Non-Current Liabilities (2013 - 2026)

Scynexis' (SCYX) quarterly Other Non-Current Liabilities came in at $800000.0 in Q2 2026, down 72.45% on a YoY basis from $2.9 million in Q2 2025, and down 95.77% quarter-over-quarter from $18.9 million in Q1 2026.

Analysis

Scynexis (SCYX) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Other Non-Current Liabilities for 13 consecutive years, with $800000.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Other Non-Current Liabilities fell 72.45% year-over-year to $800000.0; the trailing twelve-month figure through Jun 2026 stood at $800000.0 (down 72.45% YoY), and the FY2025 full-year result was $2.2 million, down 72.19% from the prior year.
  • Other Non-Current Liabilities eased to $800000.0 in Q2 2026 per SCYX's latest filing, from $18.9 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $40.3 million in Q1 2023 and bottomed at $800000.0 in Q2 2026.
  • Historically, Other Non-Current Liabilities has averaged $15.4 million across 5 years, with a median of $15.1 million in 2024.
  • The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities slumped 83.97% in 2022, then jumped 403.96% in 2023.
  • Over 5 years, Other Non-Current Liabilities stood at $18.6 million in 2022, then rose by 16.93% to $21.8 million in 2023, then plunged by 63.3% to $8.0 million in 2024, then tumbled by 72.19% to $2.2 million in 2025, then sank by 64.04% to $800000.0 in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $800000.0, $18.9 million, and $2.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 Scynexis 58.41 Mn -56.29 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 800,000.00
Mar 31, 2026 18.90 Mn
Dec 31, 2025 2.23 Mn
Sep 30, 2025 3.54 Mn
Jun 30, 2025 2.90 Mn
Mar 31, 2025 5.10 Mn
Dec 31, 2024 8.00 Mn
Sep 30, 2024 11.21 Mn
Jun 30, 2024 18.00 Mn
Mar 31, 2024 12.20 Mn
Dec 31, 2023 21.80 Mn
Sep 30, 2023 24.60 Mn
Jun 30, 2023 32.10 Mn
Mar 31, 2023 40.32 Mn
Dec 31, 2022 18.64 Mn
Sep 30, 2022 27.73 Mn
Jun 30, 2022 21.23 Mn
Mar 31, 2022 8.00 Mn
Dec 31, 2021 18.06 Mn
Sep 30, 2021 15.30 Mn